NCT03997435View on ClinicalTrials.gov

FOLFOXIRI With or Without Intensification for Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Rectal Cancer
Interventions
DRUG

Control arm

neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.

DRUG

Experimental arm

Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.

Trial Locations (3)

Unknown

RECRUITING

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

RECRUITING

Department of Oncology, Princess Margaret Hospital, Hong Kong

RECRUITING

The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
lead

CCTU

OTHER

NCT03997435 - FOLFOXIRI With or Without Intensification for Rectal Cancer | Biotech Hunter | Biotech Hunter